Hospital Mater Dei (BSP:MATD3) Selling and Marketing Expense: R$5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:MATD3 Hospital Mater Dei SA BSP:MATD3
83 GF Score
Price R$5.17
GF Value R$5.70
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Hospital Mater Dei Selling and Marketing Expense?

Hospital Mater Dei BSP:MATD3 +2.38% 83 Selling and Marketing Expense is R$5 Mil as of Jun. 2026. GuruFocus rates BSP:MATD3 with a GF Score™ of 83/100 and a GF Value™ of R$5.70 (Fairly Valued). The stock has 3 warning signs investors should review.

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Hospital Mater Dei's Selling and Marketing Expense for the three months ended in Jun. 2026 was R$2 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 was R$5 Mil.

Hospital Mater Dei Selling and Marketing Expense Related Terms

Hospital Mater Dei Selling and Marketing Expense Historical Data

* Premium members only.

The historical data trend for Hospital Mater Dei's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hospital Mater Dei Selling and Marketing Expense Chart

Hospital Mater Dei Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only 2.13 4.80 2.71 3.39 3.86

Hospital Mater Dei Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 1.06 1.33 0.90 1.85
BSP:MATD3
83GF Score
Hospital Mater Dei SA BSP:MATD3
Selling and Marketing Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hospital Mater Dei Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling and Marketing Expense of R$5 Mil mean?
Hospital Mater Dei (BSP:MATD3) has a Selling and Marketing Expense of R$5 Mil as of Jun. 2026. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Hospital Mater Dei and its competitors.
Is Hospital Mater Dei's Selling and Marketing Expense too high?
Hospital Mater Dei's current Selling and Marketing Expense is R$5 Mil. Overall, Hospital Mater Dei has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hospital Mater Dei's Selling and Marketing Expense compare to HCA and THC?
Hospital Mater Dei's Selling and Marketing Expense of R$5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling and Marketing Expense for a Healthcare Providers & Services company?
A good Selling and Marketing Expense depends on the Healthcare Providers & Services industry context. However, Selling and Marketing Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling and Marketing Expense mean?
A high Selling and Marketing Expense can signal that a stock is expensive relative to its fundamentals. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Hospital Mater Dei and its competitors. Hospital Mater Dei's current Selling and Marketing Expense is R$5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital Mater Dei stock overvalued right now?
Based on GuruFocus' analysis, Hospital Mater Dei (BSP:MATD3) is currently considered Fairly Valued. The stock's GF Value™ is R$5.70, compared to a current price of R$5.17 — trading 9.3% below its estimated fair value. The current Selling and Marketing Expense is R$5 Mil. Hospital Mater Dei's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling and Marketing Expense calculated?
Selling and Marketing Expense is calculated from a company's financial statements. For Hospital Mater Dei (BSP:MATD3), the current Selling and Marketing Expense is R$5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hospital Mater Dei (BSP:MATD3) Overvalued in 2026?

Based on GuruFocus' analysis, Hospital Mater Dei stock appears to be undervalued. The current stock price of R$5.17 is trading 9.3% below its estimated GF Value™ of R$5.70. GuruFocus considers Hospital Mater Dei to be Fairly Valued.

Key valuation signals for BSP:MATD3:

  • Selling and Marketing Expense: R$5 Mil
  • GF Value™: R$5.70 vs. price of R$5.17 (9.3% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the BSP:MATD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hospital Mater Dei Business Description

Address Rua Mato Grosso, No. 1, 100, Bairro Santo Agostinho, Belo Horizonte, MG, BRA, 30.190-081
Hospital Mater Dei SA is an integrated healthcare ecosystem that provides hospital and oncological services. The company provides a wide range of healthcare services, including hospitalizations, surgeries, oncology treatments, medical appointments, and diagnostic exams.
83GF Score

Get the complete analysis for BSP:MATD3

Selling and Marketing Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$5.17
Price
R$5.70
GF Value